Pipradrol
 | This article needs additional citations for verification. (October 2015) |
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.006.723 |
| Chemical and physical data | |
| Formula | C18H21NO |
| Molar mass | 267.372 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Pipradrol (Meratran) is a mild central nervous system stimulant (norepinephrine-dopamine reuptake inhibitor) that is no longer widely used in most countries due to concerns about its abuse potential.[2] Pipradrol is still used in some European countries and in the United States, albeit rarely.
History
[edit]Pipradrol was initially developed in the United States in the 1940s,[3] patented in 1953,[4] and marketed in the mid 1950s as the antidepressant drug Meratran[5]. It was subsequently used as an adjunct for the treatment of obesity[6] and management of senile dementia symptoms[7]. There have also been numerous reports demonstrating favorable effects on a variety of conditions such as ADHD, narcolepsy, schizophrenia, and spasmodic torticollis.[8] Pipradrol proved useful for these applications as its relatively mild stimulant effects gave it a good safety profile compared to stronger stimulants.[medical citation needed] It was also studied as an adjutant treatment for depression and schizophrenia although it was never widely used for these purposes.
Pipradrol was made illegal in many countries in the late 1970s, at the same time as many other drugs which had a history of abuse. The relatively mild stimulant effects of pipradrol meant that it was scheduled under the less restrictive classes in most countries (i.e. Class C in United Kingdom and New Zealand) but was still considered of sufficient abuse potential to be made an illegal drug. It is now an obscure compound that is virtually unknown as an illicit drug of abuse, but is still used for some scientific research, often as a comparison drug for testing other stimulants against.
Dose
[edit]Dosage is between 0.5 and 4 milligrams per day, typically taken as a single dose in the morning as the long duration of effects of pipradrol (up to 12 hours) means insomnia can be a problem especially if it is used at higher doses or taken too late in the day.[medical citation needed]
Side effects
[edit] |
Common side effects include insomnia, anorexia, tachycardia, and anxiety. Rarer side effects include dry mouth, tremor, hypertension, euphoria, depression, and very rarely psychosis or convulsions.
References
[edit]- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ "Pipradrol". go.drugbank.com. Retrieved 2023-10-22.
- ^ White, Michael W.; Archer, John R.H. (2013), "Pipradrol and Pipradrol Derivatives", Novel Psychoactive Substances, Elsevier, pp. 233–259, doi:10.1016/b978-0-12-415816-0.00010-9, ISBN 978-0-12-415816-0, retrieved 2024-10-14
- ^ Tilford, Charles H; Werner, Harold W U.S. patent 2,624,739 (1953).
- ^ FABING, HOWARD D.; HAWKINS, J. ROBERT; MOULTON, JAMES A. L. (May 1955). "CLINICAL STUDIES ON a-(2-PIPERIDYL) BENZHYDROL HYDROCHLORIDE, A NEW ANTIDEPRESSANT DRUG". American Journal of Psychiatry. 111 (11): 832–836. doi:10.1176/ajp.111.11.832. ISSN 0002-953X.
- ^ Gelvin EP, McGavack TH, Kenigsberg S (1955). "Alpha-(2-piperidyl) benzhydrol hydrochloride (pipradrol) as an adjunct in the dietary management of obesity". N Y State J Med. 55 (16): 2336–8. PMID 13244858.
- ^ "NCATS Inxight Drugs — PIPRADROL HYDROCHLORIDE". drugs.ncats.io. Retrieved 2024-10-14.
- ^ "Pipradrol". go.drugbank.com. Retrieved 2024-10-14.